This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Point-of-Delivery Drug Reconstitution Systems

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Point-of-Delivery Drug Reconstitution Systems

Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biological NCEs. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent. The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. This report examines commercial drug reconstitution devices and systems and their impact on the injectable drug delivery sector.


- Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial drug reconstitution systems

- Provides analysis of injectable drugs for reconstitution and assesses key market segments, market dynamics and market demographics

- Forecasts Injectable drug product demand by indication and therapy to 2017

- Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations

Executive Summary

Market Dynamics

Prolonging the Shelf Life of Biological Drugs

Distribution Strategies

Formulation Strategies

Lyophilization and Reconstitution at the Point of Use

Healthcare Economics and Reconstitution Systems

What's Driving the Growth in Engineered Reconstitution Systems?

Biological Drugs Proliferating

The Trend toward Self-Administration

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs